FDA: Lilly’s COVID Drug Not Expected To Work Against BQ.1, BQ.1.1

By Beth Wang / November 4, 2022 at 3:36 PM

FDA on Friday (Nov. 4) cautioned health care providers that Eli Lilly’s COVID-19 monoclonal antibody bebtelovimab is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1, which comprise about 17% and 19% of coronavirus cases in the United States, respectively.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

FDA: Lilly’s COVID Drug Not Expected To Work Against BQ.1, BQ.1.1

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.